TY  - CHAP
AU  - Miletić Vukajlović, Jadranka
AU  - Drakulić, Dunja
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2255
AB  - Parkinsonova bolest (PB) je kompleksno progresivno neurodegenerativno oboljenje sa nerazjašnjenom
etiopatogenezom. Odlikuje je, između ostalog, narušena struktura i funkcija komponenti dopaminskog sistema
u delu mozga u kome se nalaze centri za izvođenje voljnih pokreta, kogniciju i pamćenje, dok su na
ćelijskom nivo karakteristične neuroinflamacija, narušavanje strukture i funkcija mnogih organela uključujući
mitohondrije, lizozome ili transportne vezikule, poremećen redoks status, nepravilno savijanje proteina
koje uslovljava njihovo neadekvatno funkcionisanje, stvaranje unutarćelijskih depozita različitih
supstanci (molekula/jona). Obično se manifestuje kombinacijom niza motornih i nemotornih simptoma,
uključujući tremor pri mirovanju, usporenost i osiromašenost pokreta (bradikinezija), ukočenost mišića
(rigidnost) ruku, nogu i vrata, gubitak posturalnih refleksa, fleksibilan položaj tela, kao i konstipacija, urinarna
disfunkcija, impotencija, poremećaji faza sna, prekomerna dnevna pospanost, nemogućnost gutanja
pljuvačke, znojenje, mučnina, anksioznost, apatija, depresija, demencija. Dijagnostikovanje PB se vrši
posredno na osnovu prisustva minimum dva motorna simptoma i adekvatan odgovor na antiparkinson
terapiju, a sa sigurnošću se potvrđuje tek post-mortem analizama utvrđivanjem postojanja karakterističnih
patohistoloških promena u različitim regionima mozga. Kao potencijalni uzročnici njenog nastanka i
progresije izdvajaju se genski faktori, faktori spoljašnje sredine, kao i njihovo međusobno delovanje. Izazovi
PB su ne samo nemogućnost ranog uspostavljanja dijagnoze, poteškoće u procenjivanju toka bolesti,
identifikacija potencijalnih biomarkera i signalnih puteva koji su uključeni u patogenezu, njihova uloga
u kliničkoj prezentaciji bolesti, već i terapija. Iako se ovo hronično oboljenje leči različitim lekovima (farmakoterapija),
hirurškim zahvatima, i potpornim, komplementarnim i alternativnim terapijama, ni jedan
od navedenih vidova terapije ne omogućava potpuno ozdravljenje već kontrolu simptoma radi što dužeg
nezavisnog funkcionisanja obolelih.
AB  - Parkinson’s disease (PD) is a complex progressive neurodegenerative disease with uncertain etiopathogenesis.
Among others, it is characterized by impaired structure and function of components of the dopamine
system in regions of the brain responsible for performing voluntary movements, cognition and
memory; neuroinflammation; disruption of structure and function of various organelles including mitochondria,
lysosomes or transport vesicles, disturbed redox status, misfolding of proteins, intracellular deposition
of various substances (molecules/ions). Usually PD is manifested by a combination of several
motor and non-motor symptoms, including resting tremor, slowness of movement and speed (bradykinesia),
stiffness of arms, legs and neck muscles (rigidity), loss of postural reflexes, flexible body position,
along with constipation, urinary dysfunction, impotence, sleep disorders, excessive daytime sleepiness,
inability to swallow saliva, sweating, nausea, anxiety, apathy, depression, dementia. Diagnosing is performed
indirectly based on the presence of at least two motor symptoms and an adequate response to antiparkinsonian
therapy, while it can be confirmed with certainty only by post-mortem analysis according
to the existence of characteristic pathohistological changes in different regions of the brain. In PD pathogenesis
the relative contribution of genes, environmental/lifestyle factors, as well as their specific interactions
has been recognized. The challenges of PD are not only the impossibility of early diagnosis,
difficulties in assessing the course of the disease, the identification of potential biomarkers and signaling
pathways involved in pathogenesis, their role in the clinical presentation of the disease, but also the therapy.
Although the PD patients are treated with various drugs (pharmacotherapy), surgical interventions,
and supportive, complementary and alternative therapies, none of the mentioned types of therapy provide
the healing but they enable the control of the symptoms for the longest possible independent functioning
of the patients.
PB  - Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo
T2  - Trendovi u molekularnoj Biologiji
T1  - Parkinsonova bolest – dokle se stiglo?
T1  - Parkinson’s disease – state of the art
EP  - 203
IS  - 3
SP  - 184
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2255
ER  - 

@inbook{
author = "Miletić Vukajlović, Jadranka and Drakulić, Dunja",
year = "2023",
abstract = "Parkinsonova bolest (PB) je kompleksno progresivno neurodegenerativno oboljenje sa nerazjašnjenom
etiopatogenezom. Odlikuje je, između ostalog, narušena struktura i funkcija komponenti dopaminskog sistema
u delu mozga u kome se nalaze centri za izvođenje voljnih pokreta, kogniciju i pamćenje, dok su na
ćelijskom nivo karakteristične neuroinflamacija, narušavanje strukture i funkcija mnogih organela uključujući
mitohondrije, lizozome ili transportne vezikule, poremećen redoks status, nepravilno savijanje proteina
koje uslovljava njihovo neadekvatno funkcionisanje, stvaranje unutarćelijskih depozita različitih
supstanci (molekula/jona). Obično se manifestuje kombinacijom niza motornih i nemotornih simptoma,
uključujući tremor pri mirovanju, usporenost i osiromašenost pokreta (bradikinezija), ukočenost mišića
(rigidnost) ruku, nogu i vrata, gubitak posturalnih refleksa, fleksibilan položaj tela, kao i konstipacija, urinarna
disfunkcija, impotencija, poremećaji faza sna, prekomerna dnevna pospanost, nemogućnost gutanja
pljuvačke, znojenje, mučnina, anksioznost, apatija, depresija, demencija. Dijagnostikovanje PB se vrši
posredno na osnovu prisustva minimum dva motorna simptoma i adekvatan odgovor na antiparkinson
terapiju, a sa sigurnošću se potvrđuje tek post-mortem analizama utvrđivanjem postojanja karakterističnih
patohistoloških promena u različitim regionima mozga. Kao potencijalni uzročnici njenog nastanka i
progresije izdvajaju se genski faktori, faktori spoljašnje sredine, kao i njihovo međusobno delovanje. Izazovi
PB su ne samo nemogućnost ranog uspostavljanja dijagnoze, poteškoće u procenjivanju toka bolesti,
identifikacija potencijalnih biomarkera i signalnih puteva koji su uključeni u patogenezu, njihova uloga
u kliničkoj prezentaciji bolesti, već i terapija. Iako se ovo hronično oboljenje leči različitim lekovima (farmakoterapija),
hirurškim zahvatima, i potpornim, komplementarnim i alternativnim terapijama, ni jedan
od navedenih vidova terapije ne omogućava potpuno ozdravljenje već kontrolu simptoma radi što dužeg
nezavisnog funkcionisanja obolelih., Parkinson’s disease (PD) is a complex progressive neurodegenerative disease with uncertain etiopathogenesis.
Among others, it is characterized by impaired structure and function of components of the dopamine
system in regions of the brain responsible for performing voluntary movements, cognition and
memory; neuroinflammation; disruption of structure and function of various organelles including mitochondria,
lysosomes or transport vesicles, disturbed redox status, misfolding of proteins, intracellular deposition
of various substances (molecules/ions). Usually PD is manifested by a combination of several
motor and non-motor symptoms, including resting tremor, slowness of movement and speed (bradykinesia),
stiffness of arms, legs and neck muscles (rigidity), loss of postural reflexes, flexible body position,
along with constipation, urinary dysfunction, impotence, sleep disorders, excessive daytime sleepiness,
inability to swallow saliva, sweating, nausea, anxiety, apathy, depression, dementia. Diagnosing is performed
indirectly based on the presence of at least two motor symptoms and an adequate response to antiparkinsonian
therapy, while it can be confirmed with certainty only by post-mortem analysis according
to the existence of characteristic pathohistological changes in different regions of the brain. In PD pathogenesis
the relative contribution of genes, environmental/lifestyle factors, as well as their specific interactions
has been recognized. The challenges of PD are not only the impossibility of early diagnosis,
difficulties in assessing the course of the disease, the identification of potential biomarkers and signaling
pathways involved in pathogenesis, their role in the clinical presentation of the disease, but also the therapy.
Although the PD patients are treated with various drugs (pharmacotherapy), surgical interventions,
and supportive, complementary and alternative therapies, none of the mentioned types of therapy provide
the healing but they enable the control of the symptoms for the longest possible independent functioning
of the patients.",
publisher = "Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo",
journal = "Trendovi u molekularnoj Biologiji",
booktitle = "Parkinsonova bolest – dokle se stiglo?, Parkinson’s disease – state of the art",
pages = "203-184",
number = "3",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2255"
}

Miletić Vukajlović, J.,& Drakulić, D.. (2023). Parkinsonova bolest – dokle se stiglo?. in Trendovi u molekularnoj Biologiji
Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo.(3), 184-203.
https://hdl.handle.net/21.15107/rcub_imagine_2255

Miletić Vukajlović J, Drakulić D. Parkinsonova bolest – dokle se stiglo?. in Trendovi u molekularnoj Biologiji. 2023;(3):184-203.
https://hdl.handle.net/21.15107/rcub_imagine_2255 .

Miletić Vukajlović, Jadranka, Drakulić, Dunja, "Parkinsonova bolest – dokle se stiglo?" in Trendovi u molekularnoj Biologiji, no. 3 (2023):184-203,
https://hdl.handle.net/21.15107/rcub_imagine_2255 .

TY  - CHAP
AU  - Guševac Stojanović, Ivana
AU  - Drakulić, Dunja
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1820
AB  - Poremećena moždana cirkulacija, koja je karakteristična za starenje i mnoga cerebrovaskularna i/ili
neurodegenerativna oboljenja, povezuje se sa prooksidativnim i proapoptotskim promenama mnogobrojnih
biomolekula, uključujući lipide, proteine i DNK, i narušavanjem strukture i funkcije ćelija prečeone
moždane kore (PFC) i hipokampusa (HIPP). Do sada je testiran efekat brojnih jedinjenja da bi se ublažile
posledice narušenog protoka krvi kroz moždano tkivo, ali adekvatna terapija još uvek nije dostupna. Ipak,
kao jedan od mogućih terapeutika, izdvaja se steroidni hormon, progesteron (pregn-4-en-3,20-dion, P4),
za kojeg je pokazano da ispoljava zaštitne efekte u mnogim životinjskim eksperimentalnim modelima kojima
se oponašaju pojedini aspekti poremećaja strukture i funkcije moždanih ćelija primećeni kod starijih
ljudi i obolelih od cerebrovaskularnih i/ili neurodegenerativnih bolesti. Stoga, fokus ovog rada je pružanje
mogućnosti boljeg razumevanja molekulskih mehanizama delovanja P4 u mozgu u fiziološkom stanju,
kao i terapijskog potencijala koji iskazuje u animalnim modelima cerebrovaskularnih i neurodegenerativnih
bolesti, sa posebnim osvrtom na trajnu moždanu hipoperfuziju (MH) gde pokazuje regionalno-specifično
dejstvo. Iako se P4, za sada, u humanoj populaciji pokazao kao neadekvatan terapeutik u lečenju
patološkog stanja povezanog sa poremećenom moždanom cirkulacijom, dodatne kliničke studije bi obezbedile
saznanja o efektu ovog potentnog neurosteroida kod obolelih od drugih cerebrovaskularnih i/ili
neurodegenerativnih bolesti, dok bi u slučaju ohrabrujućih rezultata, P4 terapija mogla znatno olakšati
kvalitet života obolelih.
AB  - Disturbed cerebral circulation, characteristic for aging and many cerebrovascular and/or neurodegenerative
diseases, is associated with prooxidative and proapoptotic changes of various biomolecules, including
lipids, proteins and DNA, and with compromised cell structure and function in prefrontal cortex
(PFC) and hippocampus (HIPP). Numerous compounds, until today, have been tested to alleviate the outcomes
of impaired blood flow through brain tissue, but adequate therapy is not yet available. However, one
of the possible therapeutics is singled out, the steroid hormone, progesterone (pregn-4-en-3,20-dione,
P4), which has been shown to exert protective effects in many animal experimental models that mimic certain
aspects of brain structural and functional changes observed in the elderly and those suffering from
cerebrovascular and/or neurodegenerative diseases. Therefore, this paper is focused on providing a better
understanding of physiological P4-mediated brain molecular mechanisms, as well as its therapeutic
potential in animal models of cerebrovascular and neurodegenerative diseases with the emphasis on permanent
cerebral hypoperfusion (CH) where the regional-specific response is observed. Although P4 is
shown as inadequate for treating a pathological condition associated with disturbed cerebral circulation,
additional clinical studies would provide insights into the potential therapeutic capacity of this potent neurosteroid
in other cerebrovascular and/or neurodegenerative diseases and conditions. In the case of encouraging
results, P4 therapy could significantly improve the quality of patients’ life.
PB  - Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo
T2  - Trendovi u molekularnoj Biologiji
T1  - Neuroprotektivni potencijal progesterona
T1  - Neuroprotective progesterone potential
EP  - 185
IS  - 2
SP  - 168
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1820
ER  - 

@inbook{
author = "Guševac Stojanović, Ivana and Drakulić, Dunja",
year = "2022",
abstract = "Poremećena moždana cirkulacija, koja je karakteristična za starenje i mnoga cerebrovaskularna i/ili
neurodegenerativna oboljenja, povezuje se sa prooksidativnim i proapoptotskim promenama mnogobrojnih
biomolekula, uključujući lipide, proteine i DNK, i narušavanjem strukture i funkcije ćelija prečeone
moždane kore (PFC) i hipokampusa (HIPP). Do sada je testiran efekat brojnih jedinjenja da bi se ublažile
posledice narušenog protoka krvi kroz moždano tkivo, ali adekvatna terapija još uvek nije dostupna. Ipak,
kao jedan od mogućih terapeutika, izdvaja se steroidni hormon, progesteron (pregn-4-en-3,20-dion, P4),
za kojeg je pokazano da ispoljava zaštitne efekte u mnogim životinjskim eksperimentalnim modelima kojima
se oponašaju pojedini aspekti poremećaja strukture i funkcije moždanih ćelija primećeni kod starijih
ljudi i obolelih od cerebrovaskularnih i/ili neurodegenerativnih bolesti. Stoga, fokus ovog rada je pružanje
mogućnosti boljeg razumevanja molekulskih mehanizama delovanja P4 u mozgu u fiziološkom stanju,
kao i terapijskog potencijala koji iskazuje u animalnim modelima cerebrovaskularnih i neurodegenerativnih
bolesti, sa posebnim osvrtom na trajnu moždanu hipoperfuziju (MH) gde pokazuje regionalno-specifično
dejstvo. Iako se P4, za sada, u humanoj populaciji pokazao kao neadekvatan terapeutik u lečenju
patološkog stanja povezanog sa poremećenom moždanom cirkulacijom, dodatne kliničke studije bi obezbedile
saznanja o efektu ovog potentnog neurosteroida kod obolelih od drugih cerebrovaskularnih i/ili
neurodegenerativnih bolesti, dok bi u slučaju ohrabrujućih rezultata, P4 terapija mogla znatno olakšati
kvalitet života obolelih., Disturbed cerebral circulation, characteristic for aging and many cerebrovascular and/or neurodegenerative
diseases, is associated with prooxidative and proapoptotic changes of various biomolecules, including
lipids, proteins and DNA, and with compromised cell structure and function in prefrontal cortex
(PFC) and hippocampus (HIPP). Numerous compounds, until today, have been tested to alleviate the outcomes
of impaired blood flow through brain tissue, but adequate therapy is not yet available. However, one
of the possible therapeutics is singled out, the steroid hormone, progesterone (pregn-4-en-3,20-dione,
P4), which has been shown to exert protective effects in many animal experimental models that mimic certain
aspects of brain structural and functional changes observed in the elderly and those suffering from
cerebrovascular and/or neurodegenerative diseases. Therefore, this paper is focused on providing a better
understanding of physiological P4-mediated brain molecular mechanisms, as well as its therapeutic
potential in animal models of cerebrovascular and neurodegenerative diseases with the emphasis on permanent
cerebral hypoperfusion (CH) where the regional-specific response is observed. Although P4 is
shown as inadequate for treating a pathological condition associated with disturbed cerebral circulation,
additional clinical studies would provide insights into the potential therapeutic capacity of this potent neurosteroid
in other cerebrovascular and/or neurodegenerative diseases and conditions. In the case of encouraging
results, P4 therapy could significantly improve the quality of patients’ life.",
publisher = "Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo",
journal = "Trendovi u molekularnoj Biologiji",
booktitle = "Neuroprotektivni potencijal progesterona, Neuroprotective progesterone potential",
pages = "185-168",
number = "2",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1820"
}

Guševac Stojanović, I.,& Drakulić, D.. (2022). Neuroprotektivni potencijal progesterona. in Trendovi u molekularnoj Biologiji
Beograd : Institut za molekularnu genetiku i genetičko inženjerstvo.(2), 168-185.
https://hdl.handle.net/21.15107/rcub_imagine_1820

Guševac Stojanović I, Drakulić D. Neuroprotektivni potencijal progesterona. in Trendovi u molekularnoj Biologiji. 2022;(2):168-185.
https://hdl.handle.net/21.15107/rcub_imagine_1820 .

Guševac Stojanović, Ivana, Drakulić, Dunja, "Neuroprotektivni potencijal progesterona" in Trendovi u molekularnoj Biologiji, no. 2 (2022):168-185,
https://hdl.handle.net/21.15107/rcub_imagine_1820 .